Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PPA-Free Cough/Cold, Appetite Suppressant Formulations Planned

This article was originally published in The Tan Sheet

Executive Summary

Novartis Consumer Health anticipates launching Tavist Allergy/Sinus/Headache caplets in time for the spring allergy season.
Advertisement

Related Content

Children's Cough/Cold OTCs Survey Shows Limited Parental Knowledge
Children's Cough/Cold OTCs Survey Shows Limited Parental Knowledge
Tavist Line Extensions Include NDA, Monograph Products
Dimetapp Line Extensions Filling Void Of PPA Product Withdrawals
Colgate Protects Against Tech Stock Decay, Street Finds
Perrigo PPA Product Withdrawal Costs Could Reach $19 Mil.
PPA AER Underreporting Probable, NDAC Says In Vote Against GRAS Status
PPA AER Underreporting Probable, NDAC Says In Vote Against GRAS Status
PPA Increases Hemorrhagic Stroke Risk - Yale Study
Acutrim, Allerest Extensions Focus On Natural Ingredients

Topics

Advertisement
UsernamePublicRestriction

Register

PS091833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel